Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 13/20 | 0.46 |
| ▸ | MERTK | Q12866 | 13/20 | 0.46 |
| ▸ | AXL | P30530 | 6/20 | 0.46 |
| ▸ | FLT3 | P36888 | 8/20 | 0.45 |
| ▸ | GAS6 | Q14393 | 7/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450053 | 1.00 | TYRO3 (0.46) | TYRO3MERTKAXLFLT3GAS6 | |
| SCHEMBL13310866 | 0.90 | TYRO3 (0.52) | TYRO3MERTKAXLEGFRSYK | |
| SCHEMBL3463402 | 0.90 | TYRO3 (0.43) | TYRO3MERTKAXLEGFRSYK | |
| SCHEMBL13311124 | 0.88 | CSNK2A1 (0.53) | TYRO3MERTKAXLFLT3GAS6 | |
| SCHEMBL13420488 | 0.88 | CSNK2A1 (0.53) | TYRO3MERTKAXLFLT3GAS6 | |
| SCHEMBL3449062 | 0.88 | CSNK2A1 (0.53) | TYRO3MERTKAXLFLT3GAS6 | |
| SCHEMBL3449089 | 0.86 | STK17A (0.44) | AXLCSNK2A1EGFRSYK | |
| SCHEMBL3448587 | 0.85 | STK17A (0.50) | AXLCSNK2A1EGFRSYK | |
| SCHEMBL3449965 | 0.85 | P2RY12 (0.46) | FLT3EGFRKITPTK2 | |
| SCHEMBL13311563 | 0.84 | NPC1 (0.45) | CSNK2A1EGFRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | TYRO3 2798/4885MERTK 1743/4885AXL 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.